Zobrazeno 1 - 10
of 478
pro vyhledávání: '"Masahiro FUKUOKA"'
Autor:
Takayo Ota, Tomoya Fukui, Yoshiro Nakahara, Takayuki Takeda, Junji Uchino, Takako Mouri, Keita Kudo, Saki Nakajima, Tomohiro Suzumura, Masahiro Fukuoka
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3223-3233 (2020)
Background Currently used biomarkers for immunotherapy are inadequate because they are only based on tumor properties. In view of microenvironment changes by tumors, host immunity should be considered, which may result in identifying more accurate an
Externí odkaz:
https://doaj.org/article/078a03a84dfa4991824e4e520a836b94
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 100-104 (2020)
The creatinine kinase (CK)-MB assay can be used for the early diagnosis of acute coronary syndrome. We describe the case of an 82-year-old male with lung adenocarcinoma who presented with chest pain. While laboratory findings showed elevated CK-MB le
Externí odkaz:
https://doaj.org/article/d5d6596299d44245924d055f877350cd
Publikováno v:
Respirology Case Reports, Vol 9, Iss 10, Pp n/a-n/a (2021)
Abstract V‐raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto‐oncogene that regulates cell proliferation and survival. BRAF V600E‐mutated lung cancer has aggressive characteristics and is resistant to chemotherapies. Combination o
Externí odkaz:
https://doaj.org/article/767aea6c0b7e4a33b68d07118860eb60
Autor:
Fredrik Nyberg, Atsushi Ogiwara, Chris G Harbron, Takao Kawakami, Keiko Nagasaka, Sachiko Takami, Kazuya Wada, Hsiao-Kun Tu, Makiko Otsuji, Yutaka Kyono, Tae Dobashi, Yasuhiko Komatsu, Makoto Kihara, Shingo Akimoto, Ian S Peers, Marie C South, Tim Higenbottam, Masahiro Fukuoka, Koichiro Nakata, Yuichiro Ohe, Shoji Kudoh, Ib Groth Clausen, Toshihide Nishimura, György Marko-Varga, Harubumi Kato
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22062 (2011)
Interstitial lung disease (ILD) events have been reported in Japanese non-small-cell lung cancer (NSCLC) patients receiving EGFR tyrosine kinase inhibitors. We investigated proteomic biomarkers for mechanistic insights and improved prediction of ILD.
Externí odkaz:
https://doaj.org/article/af60af12639f46209edb9caf457a13c9
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 2 (2010)
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), were the first molecularly targeted agents to become clinically available for the treatment of non-small cell lung cancer (NSCLC
Externí odkaz:
https://doaj.org/article/2c94869d6352461bbebc4bfabd0ee18b
Autor:
Tomohide Tamura, Kazumasa Noda, Shinzoh Kudoh, José Baselga, Johan Vansteenkiste, Giuseppe Giaccone, Seiji Yano, Takeshi Horai, Kazuhiko Nakagawa, Ichiro Takata, Rui Ping Dong, Masahiro Fukuoka, Egbert F. Smit, Jean-Yves Douillard, Danny Rischin, Richard Eek, A. Feyereislova, Steven D. Averbuch, Yutaka Nishiwaki, Angela Macleod
Publikováno v:
Journal of Clinical Oncology. 41:1162-1171
PURPOSE To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with pretreated advanced non–small-cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45ccc160e40821bcd68e21184b9491e2
https://doi.org/10.1200/jco.22.02499
https://doi.org/10.1200/jco.22.02499
Autor:
Kazuhiko Nakagawa, Koji Ono, Masahiro Fukuoka, Yuki Yamada, Erina Hatashita, Minoru Suzuki, Isamu Okamoto, Tsutomu Iwasa
Supplementary Data from Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20467d51881070757c4c7472a94bc0c1
https://doi.org/10.1158/1078-0432.22440523
https://doi.org/10.1158/1078-0432.22440523
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Masahiro Fukuoka, Haruka Yamaguchi, Kiyoko Kuwata, Junko Tanizaki, Isamu Okamoto, Ken Takezawa
Supplementary Data from Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1becf47be73166a164e81c4a2e7978e9
https://doi.org/10.1158/1535-7163.22485189
https://doi.org/10.1158/1535-7163.22485189
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Masahiro Fukuoka, Kazuyoshi Yanagihara, Tokuzo Arao, Kiyoko Kuwata, Yuki Yamada, Erina Hatashita, Ken Takezawa, Kunio Okamoto, Takeshi Yoshida, Isamu Okamoto, Wataru Okamoto
Therapeutic strategies that target c-Src hold promise for a wide variety of cancers. We have now investigated both the effects of dasatinib, which inhibits the activity of c-Src and several other kinases, on cell growth as well as the mechanism of da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca4d3c142725765400486b145fa2272
https://doi.org/10.1158/1535-7163.c.6532190
https://doi.org/10.1158/1535-7163.c.6532190
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Masahiro Fukuoka, Haruka Yamaguchi, Kiyoko Kuwata, Junko Tanizaki, Isamu Okamoto, Ken Takezawa
Most non–small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth factor receptor (EGFR) are initially responsive to first-generation, reversible EGFR tyrosine kinase inhibitors (TKI) such as gefitinib, but they subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::005eea9a477e6a71678aabd092efd0f1
https://doi.org/10.1158/1535-7163.c.6531825
https://doi.org/10.1158/1535-7163.c.6531825